Skip to Content

VIRxSYS to Present at Phacilitate Cell & Gene Therapy Forum

(BUSINESS WIRE)--Jan 22, 2009 - VIRxSYS



  VIRxSYS to present data on its first clinical trial using lentiviral vectors in a presentation entitled Findings from Phase I/II and decisions regarding next step. The presentation will address the following:


    -- Successful delivery of a 937 base antisense sequence to HIV envelope
    -- Cumulative data on patient safety monitoring
    -- Coordination between manufacturing and clinical through the phases
    -- The next clinical trial: Phase IIb or phase III? Discussions with the regulator
    -- Defining the optimum patient population
    -- Re-imbursement models


  VIRxSYS' novel lentiviral vector platform and ongoing clinical trials show great promise in a safe and effective treatment for people with HIV. The company's gene therapy treatment, VRX496, can be replicated on a larger scale and is encouraging as a means to suppress and block HIV. To date, VRX496 has been administered in 61 patients, representing an accumulative patient safety monitoring of 142 patient years. VRX496 is different from previous gene therapies because it uses a lentiviral vector derived from HIV-1 itself.




  VIRxSYS EVP of scientific and clinical affairs, Gerard J. McGarrity, PhD. Dr. McGarrity has over 20 years experience in the biotechnology industry and has authored more than 160 scientific publications.




  The 2009 Phaciliate Cell & Gene Therapy Forum, The Grand Hyatt Hotel, Washington, D.C.


  Monday, January 26, 2009. VIRxSYS presentation will be held in Focus Session 2 at 2:55 p.m.


Contact: For VIRxSYS
Lynn Granito, 212-255-5340


Posted: January 2009